Gastroenterology

Latest News

doctor talking to patient about biosimilars | Image credit: Suteren Studio - stock.adobe.com
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD

February 15th 2025

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.

market dynamics | Image credit: TStudious - stock.adobe.com
Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential

February 10th 2025

colorectal cancer | Image credit: Dr_Microbe - stock.adobe.com
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

February 8th 2025

syringe biosimilar | Image credit: Luluraschi - stock.adobe.com
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars

February 5th 2025

Wezlana | background image: autoinjector pen | Image credit: nazif - stock.adobe.com
Welcome Wezlana: The First Stelara Biosimilar to Launch in the US

January 31st 2025

© 2025 MJH Life Sciences

All rights reserved.